Abstract | Oxidative stress is increased in systemic lupus erythematosus (SLE), and it contributes to immune system dysregulation, abnormal activation and processing of cell-death signals, autoantibody production and fatal comorbidities. Mitochondrial dysfunction in T cells promotes the release of highly diffusible inflammatory lipid hydroperoxides, which spread oxidative stress to other intracellular organelles and through the bloodstream. Oxidative modification of self antigens triggers autoimmunity, and the degree of such modification of serum proteins shows striking correlation with disease activity and organ damage in SLE. In T cells from patients with SLE and animal models of the disease, glutathione, the main intracellular antioxidant, is depleted and serine/threonine-protein kinase mTOR undergoes redox-dependent activation. In turn, reversal of glutathione depletion by application of its amino acid precursor, N-acetylcysteine, improves disease activity in lupus-prone mice; pilot studies in patients with SLE have yielded positive results that warrant further research. Blocking mTOR activation in T cells could conceivably provide a well-tolerated and inexpensive alternative approach to B-cell blockade and traditional immunosuppressive treatments. Nevertheless, compartmentalized oxidative stress in self-reactive T cells, B cells and phagocytic cells might serve to limit autoimmunity and its inhibition could be detrimental. Antioxidant therapy might also be useful in ameliorating damage caused by other treatments. This Review thus seeks to critically evaluate the complexity of oxidative stress and its relevance to the pathogenesis and treatment of SLE.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease of unknown aetiology, and for which approved therapies are inadequate. Current treatments rely on the use of cytotoxic, anti-proliferative, and anti-metabolite drugs as well as the depletion or inactivation of B cells (Supplementary Table 1) . 1 The pathogenesis of SLE is attributed to dysfunction of T cells, B cells, dendritic cells, macrophages and neutrophils, secondary to genetic and/or environmental factors. 2 In broad terms, molecular mimicry (that is, crossreactivity between exogenous and self antigens), aberrant exposure or modification of endogenous antigens, accompanied by expression of autoantibodies, leads to the formation of pathogenic immune complexes that mediate tissue damage in SLE. 3 Defined as an imbalance between the production and neutralization of reactive oxygen intermediates (ROI), 4 and governed by a combination of inherent and environ mental factors, oxidative stress is thought to underlie some of the aberrant exposure of and reaction to cell-death signals that characterizes SLE pathology. Abnormal activation and processing of cell-death signals by the immune system triggers the release of nuclear debris from apoptotic and necrotic cells and stimulates the production of antinuclear (for example, anti-Ro and anti-DNA) antibodies, with subsequent inflammation, organ damage and pathology.
2-5 Excessive production and ineffective clearance of ROI are implicated in the development of SLE.
ROI mostly originate from mitochondria, and T cells from patients with SLE exhibit mitochondrial dysfunction, characterized by mitochondrial hyperpolarization (that is, elevated mitochondrial transmembrane potential [∆Ψm]) ( Figure 1a) . [6] [7] [8] Increased production of ROI 8 or diminished levels of reduced glutathione (an inverse marker of cellular oxidative toxicity) have been found in peripheral blood lymphocytes (PBL) from patients with SLE. 6-10 Besides mitochondrial production, ROI can also be generated by NADPH oxidase (NOX) enzymes in phagocytes and, to a lesser extent, in endothelial cells, T cells and B cells, [11] [12] [13] as well as by environmental oxidants. Genetic factors that compromise antioxidant defences against ROI 14, 15 or control endogenous ROI production by altering mitochondrial homeostasis [15] [16] [17] have been linked to SLE pathology. 18, 19 Once initiated, oxidative damage can be propagated via numerous molecular targets. Products of these cascades of oxidative modification are associated with disease activity, organ damage, and comorbidities in SLE. Protection against ROI is normally afforded by intra cellular antioxidant systems that are primarily dependent on the availability of reduced glutathione (Figure 1b) . 4 Boosting this availability, as discussed in the section "NAC and rapamycin", is a developmental strategy in SLE therapy and acts upstream of oxidative stress. Downstream pathways also represent potential points of intervention ( Figure 2 ). Oxidative stress contributes substantially to cardiovascular disease (CVD), 20 which-alongside renal failure and infections-is a major cause of morbidity and mortality in SLE. 21 Antioxidant therapy can improve cardio vascular outcomes in patients with end-stage renal disease. 22 Although the evidence that oxidative stress is increased in SLE and that it contributes to immune dysregulation, organ damage, and fatal comorbidities is overwhelming, compartmentalized oxidative stress is necessary and its induction can be beneficial. Phagocytic cells use oxidative stress to eliminate pathogenic organisms, whereas cytotoxic drugs-used with the intent of eliminating autoreactive cells and thus restraining immunity-induce oxidative stress and cell death. Thus, where therapeutic oxidative stress is required, antioxidant therapies have a role in limiting the toxicity of i mmunosuppressant therapies. 23 This Review, therefore, critically evaluates the complexity of oxidative stress in SLE. The molecular pathways that generate oxidative stress are examined, with a focus on mitochondrial dysfunction in T cells-as a source of ROI and of proinflammatory necrotic debris. Propagation of oxidative stress through the bloodstream by reactive aldehydes, and the roles of these pro-oxidant molecules with respect to SLE pathogenesis and the generation of autoreactivity to self-antigens, alterations in signal transduction and cytokine production are discussed. Subsequent injury to organs such as the kidney and the skin, and contributions to life-shortening comorbidities, such as atherosclerosis, thrombosis, and infections are outlined. Counterbalancing discussion of these pathogenic pathways, the potential benefits of compartmentalized oxidative stress, in killing of infectious organisms by phagocytic cells and limiting immune system activation, are also examined. Checkpoints of oxidative stress as regulators of pathogenesis, biomarkers of disease activity, and targets of treatment in SLE are evaluated.
Endogenous sources of oxidative stress
Increased ROI production in mitochondria Increased production of ROI 8 or diminished levels of reduced glutathione (Glu-Cys-Gly tripeptide), which is oxidized to glutathione disulphide (GSSG) by ROI and can thus serve as an inverse marker of redox toxicity, reveal cellular oxidative stress. In mi tochondria-the main source of ROI-transfer of electrons to molecular oxygen during electron transport chain (ETC) activity generates ROI including superoxide anion, O 2
•-( Figure 1a ). ETC activity generates electrical energy, stored as ∆Ψm, that generates ATP during o xidative phosphorylation. 24 ∆Ψm is regulated by o xidationreductio n equilibria of ROI, pyridine nucleotides (NADH-NAD + and NADPH-NADP + ) and g lutathione-GSSG. 4 Enabling maintenance of ∆Ψm, the pentose phosphate pathway provides the NADPH required by catalase, glutathione reductase, and NO synthase (NOS) enzymes (Figure 1b) . 4 In a state of mitochondrial hyperpolarization, H + ions are extruded from the mito chondrial matrix and cytochromes within the ETC become more reduced, promoting production of ROI and generating oxidative stress (Figure 1a ). 24 The most damaging ROI are the hydroxyl radical, OH
•-and O 2 •-; the latter can be converted into relatively stable, nonradical hydrogen peroxide (H 2 O 2 ) by super oxide dismutases and then into water by catalase. As OH
•-cannot be eliminated without causing oxidative damage, its formation needs to be prevented by neutral izing the upstream sources O 2
•-and H 2 O 2 . OH •-is formed in the presence of a metal ion through the Fenton reaction or triggered by UV light. 25 Because of its short half-life (10 -9 seconds at 37 °C), 26 OH •-attacks molecules in the vicinity of its formation, resulting in immediate damage to proteins, nucleic acids, and lipids. 25 Genetic data implicate disrupted mitochondrial homeo stasis in SLE. In 2012, a mouse gene at Sle1c2 (a sub-locus of the major lupus susceptibility locus Sle1) was identified as oestrogen-related receptor γ, encoding an orphan nuclear receptor that regulates oxidative metabolism and mitochondrial function-reduced expression of the gene in T cells caused greater mitochondrial mass, as estimated by increased voltage-dependent anion channel protein content. 15 Similarly, non-synonymous poly morphisms in human mito chondrial DNA encoding components of ETC complexes I and V have been associated with SLE. 17 Furthermore, inactive alleles of UCP2, which encodes mitochondrial uncoupling protein 2-a protein that reduces oxidative stress-confer predisposition to several auto immune diseases, including multiple s clerosis, rheumatoid arthritis (RA), SLE, granulo matosis with poly angiitis, Crohn disease, and ulcerative colitis. 16 Increased production of ROI may also originate from the accumulation of mitochondria due to increased biogenesis 27 and diminished turnover of mitochondria in lupus T cells. 28 According to an evaluation of T cells from patients with SLE (n = 33) and from lupusprone mice, the latter effect is caused by T-cell depletion of dynamin-1-like protein (also known as dynaminrelated protein 1, DRP1), an initiator of mitochondrial fission and mitophagy, as a consequence of overexpression of Ras-related protein Rab4A (encoded by RAB4A). 28 Mitophagy, an autophagic process in which mitochondria are targeted for lyso somal degrada tion, is thought to help maintain functional and structural integrity.
28,29
Key points ■ Oxidative stress-generated through multiple mechanisms in a cell-typespecific manner-is a substantial contributor to disease pathogenesis, organ damage and comorbidities in patients with systemic lupus erythematosus (SLE) ■ Pathways of oxidative pathogenesis, such as oxidative modification of self antigens and T-cell dysfunction, have been identified ■ Organ systems in which the clinical importance of oxidative damage in SLE has been recognized include the cardiovascular and renal systems and the skin ■ Biomarkers of oxidative stress correlate directly with disease activity in SLE ■ Depletion of glutathione (reflecting oxidative stress) might have a pathogenic role; its reversal by N-acetylcysteine seems to have therapeutic benefit in mouse models and patients with SLE
Extramitochondrial sources of oxidative stress Besides ROI, redox signalling also involves reactive nitrogen intermediates (RNI), such as NO and peroxy nitrite (ONOO •- , which is generated by the reaction of NO with O 2
•-
). NO is synthesized from L-arginine by NOS, using NADPH as a cofactor. 4 Functionally crucial cy steine residues of NOS are compromised by oxidative stress, which increases S-glutathionylation-attachment of gluta thione to cysteine through thiol-disulphid e exchange with GSSG. 30 S-glutathionylation of specific cysteine residues in the reductase domain of the endothelial isoform of NOS (eNOS), which is expressed in T cells, 27 switches production from NO to O 2
•-, g enerating oxidative stress. 31 NOX enzymes are another immune-cell source of ROI. Macrophages and granulocytes express NOX2, which produces O 2
•-for the killing of phagocytosed bacteria.
11
NOX2 is less clear as a source of ROI in T cells, 11 but studies in mice have indicated that its expression might be induced by T-cell receptor (TCR) stimulation. 12 Diminished antioxidant defences Antioxidant defences are dependent upon de novo synthesis of glutathione and thioredoxin, both of which can be regenerated at the expense of NADPH ( Figure 1b , Figure 2 ). NADPH itself is primarily produced through the metabolism of glucose via the pentose phosphate pathway. 4 Besides factors that diminish the availability of these factors, loss of endogenous antioxidant enzyme activities also predispose to SLE. For example, female mice lacking nuclear factor erythroid 2-related factor 2 (Nrf2), a transcriptional activator of antioxidant and phase II drug metabolizing enzymes, have reduced lifespan and increased lipid peroxidation, with development of anti-DNA autoantibodies, splenomegaly, mesangial deposits and massive granular deposits of IgG, IgM, and C3 along renal capillary walls, and glomerulonephritis. 18 A 2010 study involving 362 patients with childhoodonset SLE and 379 controls linked a polymorphism of NRF2 to the risk of nephritis in SLE. 32 Pharmacological stimulation of Nrf2 has subsequently been found to improve nephritis in lupus prone-mice. 33 Similarly, genetic polymorphism of the detoxifying enzyme g lutathione S-transferase has been linked to SLE. 19 Mitochondrial dysfunction 6 and glutathione depletion can be detected in T cells from patients with SLE. 6,9,10, 35 The oxidative stress evidenced by these findings can promote autoimmunity by modulating signal transduction and cytokine production within the originating T cells, and by triggering autoreactivity to self-antigens.
Environmental sources of oxidative stress
Autoantigenesis in SLE has been attributed, at least in part, to post-translational modification of self-antigens secondary to environmental triggers such as ultraviolet radiation, infection and chemical exposure. 36 Autoantigens are created during cell death, typically through enzymatic cleavage, as with Ro, 36, 37 or generated by oxidative modification, as for oxidized DNA. 38 Present in circulating immune complexes in patients with SLE, 39 oxidized DNA is also found in necrotic debris, which is 
). O 2
•-is not membrane permeable and is converted into H 2 O 2 by SOD2 within the mitochondria. H 2 O 2 is further neutralized into H 2 O by catalase at the expense of NADPH, but can also diffuse through membranes. 25 Excess H 2 O 2 is transformed into highly toxic OH
•-through the Fenton reaction. OH •-damages lipids and other macromolecules in the immediate vicinity and generates diffusible and highly toxic lipid aldehydes, which spread oxidative stress from mitochondria to other intracellular organelles and through the bloodstream. b | Redox mechanisms that control oxidative stress. Glutathione metabolism regulates mitochondrial hyperpolarization, via S-glutathionylation of ETC complex 1, which increases production of O 2
•-
. Reduced glutathione is regenerated at the expense of NADPH, which is primarily produced through the pentose phosphate pathway. 4 Transaldolase activity, which is increased in T cells from patients with SLE, 10 has been associated with depletion of NADPH and glutathione and with mitochondrial hyperpolarization. 134 Abbreviations: ETC, electron transport chain; ROI, reactive oxygen intermediates; SLE, systemic lupus erythematosus; SOD2, superoxide dismutase [Mn], mitochondrial. more pro-inflammatory than apoptotic debris. 41 Indeed, in lupus-susceptible mice, systemic autoimmune disease is induced by dendritic cells that have captured necrotic but not apoptotic debris. 42 Here we review how oxidative stress is triggered by environmental factors, such as viruses and UV, and facilitated by genetic factors that influence generation or neutralization of ROI.
Viral infection
Infectious agents, particularly viruses, have long been implicated in SLE pathogenesis: initial manifestations and disease flares of SLE resemble the febrile illness of viral infection; immune responses in SLE can be crossreactive between viral and self-antigens; and viral nucleic acids are more prevalent in blood and tissue samples of patients with SLE than in healthy controls. 42 Epstein-Barr virus is associated with autoimmune disorders, including SLE; 38 furthermore, the immunodeficient state of patients with SLE is similar to that induced by infection with HIV with regard to involvement of endogenous retro viruses 42 and other retroelements. 43 CD4 + T cells from patients with SLE 10 and from people infected by HIV-1 show activation of the HRES-1 locus containing RAB4A. 44 As we discuss in the section "Altered signal transduction: mTOR and TCR", redox-dependent overexpression of RAB4A mediates downregulation of T-cell surface glyco proteins CD4 and CD3ζ, changes that underlie defective T-cell receptor (TCR) signalling in both conditions (Figure 3 ).
10,44
One potential pathogenic mechanism by which oxidative stress seems to combine with viral infection to induce SLE involves inactivation of anti-retroviral defences. DNA reverse-transcribed from endogenous retroviruses is metabolized by 3' repair exonuclease 1 (TREX1), and inactivating mutations of TREX1 have been documented in a rare form of SLE, termed chilblain lupus.
43 TREX1 also degrades HIV-derived DNA and might protect from viral infections. 45 Translocating from the endoplasmic reticulum to the nucleus upon oxidative stress, 43 TREX1 activity is inhibited by cyclopurine deoxynucleoside photo products generated by UV-induced ROI. 46 Thus, oxidative stress might lead to a functional TREX1 deficiency and persistence of viral DNA that contributes to immune-complex formation in SLE. 42 
Bacterial infection
Oxidative stress contributes to the destruction of organisms in phagocytic cells: ROI, generated by the respiratory burst with the involvement of NOX2, participate in elimination of bacteria by neutrophils. Leftover DNA from failure to clear bacteria, as a result of defective ROI generation, is thought to chronically stimulate the innate immune system and trigger SLE. 47 Conversely, however, ROI also induce formation of neutrophil extracellular traps (NETs) involved in NETosis, a specialized form of cell death that is implicated in aberrant exposure of antigens and SLE pathogenesis (roles of neutrophils in SLE have been reviewed in this journal 48 ). 49, 50 Chronic granulomatous disease (CGD)-associated with recurrent bacterial infections and most commonly caused by NOX2 deficiency in phagocytic cells-has been linked with lupus. 10 cases of discoid lupus and 2 cases of SLE were reported in a national registry of 368 patients with CGD; the association with discoid lupus was significant only in those with X chromosome-linked recessive CGD, and not in autosomal chromosome-linked recessive CGD (19/219 versus 1/71; P <0.01). 51 Supporting a link between defective neutrophil ROI generation and SLE, Nox2 deficiency exacerbated lupus disease activity in MRL/lpr mice, through inhibiting NET formation and NETosis). 52 Paradoxically, however, NETosis seems to be increased and associated with endothelial damage in patients with SLE; 50 factors that underlie this increase, and whether the process is r epresented by the MRL/lpr mouse model, remain unknown.
Besides the link with CGD, other genetic data implicate NOX2 defects in SLE. A hypoactive C242T polymorphism in CYBB, encoding the NOX2 subunit cytochrome b-245 heavy chain has been associated with SLE in a Chinese population. 53 Similarly, polymorphism of NCF2, encoding a 67-kilodalton activating Upstream of oxidative stress, exposure to NO and/or depletion of glutathione generates ROI, which cause MHP, mitochondrial biogenesis and oxidative stress. In addition to biogenesis, an increase in the number of T-cell mitochondria in SLE has also been attributed to reduced mitophagy. 28 NADPH is generated by the pentose phosphate pathway and is required both to generate NO and to regenerate glutathione. The glutathione precursor NAC is thought to work upstream of oxidative stress by replenishing glutathione and preventing MHP. mTOR is a sensor of MHP but precisely how it is activated by oxidative stress, and thus how NAC prevents its activation, is currently unclear. Downstream of oxidative stress, mTOR activates Rab4A and associated endocytic recycling of CD3ζ. 10 These changes alter intracellular signal transduction and T-cell lineage specification, causing contraction of T H 1-cell, T REG -cell and CD8 + T-cell subsets, and expansion of T H 2-cell, T H 17-cell and CD4 -
CD8
-T-cell subsets. 34, 89 Rapamycin prevents the activation of mTOR without affecting oxidative stress. Abbreviations: FcεRIγ, high affinity immunoglobulin ε receptor subunit β, γ chain; MHP, mitochondrial hyperpolarization; mTOR, serine/threonine-protein kinase mTOR; ROI, reactive oxygen intermediates; SLE, systemic lupus erythematosus; T REG cell, regulatory T cell.
cytosolic subunit of NOX2, has been associated with SLE in a Chinese cohort, 54 and a loss-of-function His389Gln mutation of NCF2 has been linked to SLE in US patients. 55 NOX2 deficiency in the context of T-cell dysfunction is discussed in the next section.
Oxidative stress and T-cell dysfunction
We have discussed how excessive oxidative stress can arise in patients with SLE, and how it can lead to persistence of bacterial and viral antigens. ROI, originally regarded only as toxic by-products of aerobic existence, are now recognized as essential modulators of various signal-transduction pathways, including epigenetic regulation of gene transcription, 56 production of regulatory microRNA, 57 control of mRNA translation 58 and protein folding, 59 as well as degradation and recycling of proteins and organelles via autophagy. 60 In accordance with these diverse functions, oxidative stress seems to mediate T-cell dysfunction in SLE at multiple levels. Such T-cell defects result in aberrant immune responses and, in concert with the products of oxidative auto antigenesis, are thought to elicit the inflammatory pathology and comorbidities of SLE.
Lineage and cytokine shifts As discussed under "Bacterial infection", NOX2 deficiency is implicated in defective clearance of pathogenic antigens, but it is also implicated in altered T-cell responses in SLE. Activation of purified naive CD4 + T cells from Nox2-deficient mice led to augmented levels of IFN-γ and diminished IL-4 production, in comparison with wild-type cells. 61 An increased expression ratio of the T H 1 cell-specific T-box transcription factor TBX21 (also known as T-bet) over the T H 2 cell-specific trans-acting T-cell-specific transcription factor GATA-3 in the absence of Nox2 is consistent with skewing of naive T-cell development to a T H 1-cell response. 61, 62 T cells from patients with SLE and animal models of the disease, however, exhibit defective production of T H 1 cytokines IL-2 2 and IFN-γ, 63 and increased production of T H 2 cytokines IL-4 62-65 and IL-10, 8,66 favouring B-cell activation and ANA production. 67 Thus, the shifts in cytokine expression patterns that occur in SLE are consistent with promotion of IL-4 production and T H 2-cell development by oxidative stress. 68 In support of the influence of oxidative status on T-cell development, glutathione de pletion-that is, diminished antioxidant defences-also favours T H 1-to-T H 2 polarization of T-cell develop ment. 37 Oxidative stress is associated with increased mitochondrial biogenesis and Ca 2+ storage, 69 which can enhance the activity of calmodulin-dependent kinase IV and of cAMP response element modulator (CREM), thus suppressing expression of IL-2 and promoting that of IL-17 in lupus T cells (Figure 4 ). Therefore, mechanisms by which oxidative stress induces such T-cell alterations are discussed th roughout this section.
Regulation of gene transcription
Epigenetic mechanisms-DNA methylation, methyl and acetyl modification of histones, ADP-ribosylation and activity of non-coding RNA-are implicated in SLE. 70 Hypomethylation of DNA in T cells contributes to pathogenesis in patients with SLE 67 and in lupusprone mice. 72 Changes to histone acetylation status and the activity of transcription factors also govern altered transcription patterns in SLE. These factors combine to result in altered T-cell signalling and skewing of lineage development in SLE.
DNA hypomethylation
Two pathways by which oxidative stress might lead to DNA hypomethylation in SLE have emerged; the first involves downregulated activity of DNA ( cytosine-5)-methyltransferase 1 (DNMT1). A 2012 study using CD4 + T cells from patients with active SLE identified oxidative stress as a cause of demethylation of CD70, with consequent overexpression of CD70 antigen, and provided insights into the signalling events involved. Production of ONOO
•-increased the nitration of protein kinase Cδ-preventing its phosphorylation-and in turn inhibited ERK-dependent activation of DNMT1. 72 The alternative mechanism of hypomethylation involves restricted availability of S-adenosylmethionine (SAM), which serves as Figure 3 | Molecular targets of oxidative stress in T-cell signal transduction. The source of oxidative stress, ROI, primarily originate from mitochondria; small amounts can also be generated by NOX activity following TCR stimulation. 11, 12 MHP is induced by oxidative stress and activates mTOR, which in turn promotes T-cell activation via Rab4A-mediated downregulation of the TCR component CD3ζ 10 and increased calcium flux. 92 Activated mTOR inhibits DNMT1; subsequent promoter hypomethylation suppresses the transcription of FOXP3, which is required for T REG -cell development. Oxidative stress and associated changes to calcium storage also activate CREM, which suppresses IL-2 and enhances IL-17 promoter activity; these changes result in T H 1-to-T H 17 skewing in the T-cell compartment, as shown in a methyl donor for methylation of DNA and histones, as a consequence of lack of glutathione. 73 T-cell DNA hypomethylation, howsoever caused, promotes inflammation. DNA is preferentially methylated at CpG dinucleotide islands, inhibiting binding of the proinflammatory transcription factor nuclear factor κB (NFκB); hypomethylation thus promotes NFκB signalling. 74 FoxP3, conversely, is an anti-inflammatory transcription factor whose expression in mouse regulatory T (T REG ) cells is maintained by serine/threonineprotein kinase mTOR-sensitive methylation of the Foxp3 promoter, and is thus diminished in the absence of methylation. 75 
Histone modifications
Histone acetyltransferases (HATs) acetylate specific lysine residues on N-terminal tails of core histones, thereby uncoiling the DNA and increasing accessibility to transcription factors, whereas histone deacetylases (HDACs) generally repress gene transcription. 56 Histone acetylation status is affected by oxidative stress; reversing the consequent changes to gene transcription is emerging as a potential therapeutic approach in SLE. Oxidative stress causes, for example, proteolytic degradation of the HDAC NAD-dependent protein deacetylase sirtuin-1. 76 Importantly for the relevance of such pathways in SLE, pharmacological reversal of histone deacetylation through HDAC inhibition improves lupus disease activity in mice. 77 Several potential new HDAC inhibitors are under investigation for a range of purposes; for example, the endogenous compound β-hydroxybutyrate has substantial antioxidant properties in mice via inducing the expression of Sod2 and catalase. 78 Another natural compound, sulphurophane-found at high levels in broccoli-inhibits HDAC when coupled to cysteine or N-acetylcysteine (NAC). 79 Transcription factor activation As mentioned above, NFκB is a focal point in the signal transduction cascades that mediate inflammatory cues from antigen receptors on T cells and B cells, 80 and from Toll-like receptors (TLRs) on cells of the innate immune system. 47 Besides hypomethylation-driven activation of NFκB-sensitive genes, other oxidation-induced alterations in transcription factor programmes are implicated in SLE, some following the identification of lupus susceptibility genes. Among these pathways, 81 oxidative stress modulates activation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) cascade. 82 Activating phosphorylation of STAT3 is induced in human PBLs by oxidative stress, 83 and in mice, oxidative-stress induced mitochondrial translocation of Stat3 provides feedback regulation of ROI production by modulating ETC activity. 84 Expression of STAT3 is increased both in T cells from patients with SLE 85 and in B cells from mouse models of the disease.
86
STAT3-dependent signals have key roles in the differentiation of human type 17 T helper (T H 17) cells, 87 which are thought to mediate nephritis in patients with SLE via the production of IL-17.
2 Similarly, STAT4 expression 88 and the development of T H 1 cells are responsive to oxidative stress via mTOR, 89 a sensor of mitochondrial dysfunction.
10, 90 Redox-controlled activation of mTORdiscussed further in the next section-thus represents a key mechanism in T-cell lineage specification and po tentially in SLE pathogenesis (Figure 4 ).
Altered signal transduction: mTOR and TCR
As we have mentioned, T cells from patients with SLE exhibit persistent mitochondrial hyperpolarization and oxidative stress, 6 and insights into how ROI can alter T-cell functions is accumulating. Physiological TCR signal transduction requires T-cell surface glyco protein CD3ζ chain, which is susceptible to ROI-induced degradation 91 by endocytic recycling to lysosomes.
10 Consequent to this degradation, CD3ζ is replaced by γ chains of the high affinity immunoglobulin ε receptor subunit β (FcεRIγ), which facilitate the recruitment of Syk and flux of Ca 2+ upon TCR activation.
2 mTOR, which serves as a sensor of ∆Ψm 90 and is markedly activated in T cells from patients with SLE, 7,10,34 seems to mediate the loss of CD3ζ. In six 10 and nine 92 patients with SLE effectively treated by mTOR blockade with rapa mycin, inhibition of mTOR normalized T-cell Ca 2+ flux, without influencing mitochondrial hyperpolarization. In turn, mTOR was found to activate the small GTPase Rab4A, which regulates endocytic r ecycling and causes lysosomal degradation of CD4 and CD3ζ in T cells from patients with SLE. 10 The relative availability of CD3ζ and FcεRIγ for TCR signal transduction in SLE is also influenced by altered phosphorylation, as discussed in a proximate section of this manuscript, whereas therapeutic targeting of mTOR activation is d iscussed under "NAC and rapamycin".
Upstream of mTOR
Alterations in mitochondrial and endocytic recycling gene expression patterns have been detected, and validated at protein and mechanistic levels, in naive T cells from patients with SLE.
10 Among these changes, increased expression of the mitochondrial proteins voltage-dependent anion-selective channel protein 1 and superoxide dismutase 10 is consistent with increased mitochondrial mass 69 and oxidative stress in T cells in SLE.
8 Also overexpressed and likely to act upstream of mitochondrial hyperpolarization in SLE is the pentose phosphate pathway enzyme transaldolase (TAL), 10 which is a metabolic regulator of Δψ m . 93 Expression of NOSinteracting protein (NOSIP), which inhibits activity of eNOS and NO production, is reduced in T cells in SLE. Expression of neither TAL nor NOSIP is affected by ra pamycin treatment.
10
Altered phosphorylation Experiments using primary human T cells from healthy donors have shown that oxidative stress stimulates expression of serine/threonine-protein phosphatase 2A (PP2A) catalytic subunit α isoform by diminishing DNMT1 activity and thus causing demethylation of the PPP2CA promoter. 94 PP2A dephosphorylates ETS-related transcription factor Elf-1 at Thr231; increased PP2A activity reduces binding of Elf-1 to promoters in two of its target genes, those encoding CD3ζ and FcεRIγ, thus reducing the expression of the former and increasing the expression of the latter. 95 By facilitating 'exchange' of these TCR signalling components, PP2A promotes T H 2-polarization of T-cell lineage development in SLE.
2
Increased PP2A activity as a consequence of oxidative stress seems to also skew T H 1-cell cytokine production, away from IL-2 expression toward increased production of IL-17. PP2A also dephosphorylates cyclic AMPresponsive element-binding protein 1 (CREB1) and reduces its binding to the IL-2 promoter.
2 Oxidative stress also contributes to diminished IL-2 production through enhanced Ca 2+ signalling. In particular, increased mitochondrial biogenesis and accumulation of mitochondria allow for greater Ca 2+ storage 30 that may enhance the activity of calmodulin-dependent kinase IV and CREM, which in tandem suppress IL-2 and promote IL-17 expression in lupus T cells. 
Oxidative autoantigenesis
In addition to causing altered T-cell signalling and develop ment, oxidative stress is implicated in SLE pathology via the oxidative modification of self antigens, leading to autoimmunity. Evidence for the propagation of oxidative autoantigenesis through the circulation, and how this process triggers inflammation, organ damage and comorbidities in SLE is discussed in this section. Oxidative autoantigenic processes relevant to SLE include: the accumulation of oxidized HDL cholesterol (oxHDL) in the blood; oxidation of β2 glycoprotein I (β2GPI); 96 modification of polyunsaturated fatty acids and generation of autoantibodies crossreactive with DNA; 97 and UV light-triggered autoantigenicity of Ro. 98 Propagation of oxidative stress Lipid peroxidation in mitochondrial, lysosomal and cell membranes by ROI generates reactive aldehydes including malondialdehyde and 4-hydroxy-2-nonenal (HNE), which can 'spread' oxidative damage through the circulation. Products of these cascades of oxidative modification can be detected in the circulation of patients with SLE, and include advanced glycation end products (AGE) 99 and oxHDL. 100 Modification of serum albumin by HNE reflects oxidative stress 101 and its extent c orrelates with disease activity in SLE.
Autoantigenesis and inflammation
The production of hallmark SLE autoantibodies can be triggered by oxidative stress. UV light, for example, triggers the autoantigenicity of Ro, which is displayed in cell surface blebs during apoptosis, 98 and the triggering role of oxidative stress in this process is evidenced by the stimulation of Ro immunogenicity through direct treatment with HNE. 103, 104 Anti-DNA antibodies form in response to stimulation of the B-cell receptor and TLRs by DNA, particularly oxidized DNA, 39 which is released from apoptotic and necrotic cells and in NETs. 50 HNE also oxidizes β2GPI, increasing its immunogenicity via a T H 1 cell-mediated immunological mechanism and thus promoting the production of anti-β2GPI antibodies and the development of antiphospholipid syndrome (APS), which represents a substantial comorbidity in SLE. 96 In the MRL/lpr mouse model of SLE, the reactive aldehyde 4-oxo-2-nonenal (ONE) was identified as a source of autoantigenic epitopes and autoimmunity. 97 Bovine serum albumin became crossreactive with sera from the mice after it was incubated with peroxidized polyunsaturated fatty acids; anti-ONE reactivity was detected and a subset of anti-DNA antibodies in the mice was found to be crossreactive with ONE-specific epitopes. 97 Comorbidities and organ damage In addition to spreading inflammation through the bloodstream, mediators of oxidative stress contribute to damage in various organ systems. Free thiol-containing β2GPI protects endothelial cells from oxidative stressinduced cell death 104 and facilitates the phago cytosis of phosphatidylserine-coated apoptotic particles by macrophages; 105 thus, oxidation of β2GPI promotes not only thrombosis but also endothelium damage, the accumulation of apoptotic bodies and accelerated atherosclerosis. CVD is associated with renal disease both in the general population and in patients with SLE. 106 
Renal disease
Elevated malondialdehyde concentrations and diminished vitamin C levels indicate oxidative stress in the plasma of patients with lupus nephritis, 107 in whom oxidative stress has been identified as a major contributor to organ damage. 33, 108, 109 Reflected by a diminished glutathione:GSSG ratio in the kidneys of the female B/W mouse model of SLE, 111 oxidative stress may inflict renal damage via production of TNF by infiltrating macrophages. In NZB/NZW mice with IFNα-induced lupus nephritis, TNF blockade reduced oxidative stress and renal pathology. 111 Although the treatment stabilized nephritis and markedly prolonged survival, autoantibody production and systemic immune activation were not inhibited, suggesting that TNF might be a tissue-specific mediator of oxidative stress-associated organ damage. 111 Oxidative stress is also reported to contribute to hypertension and proteinuria in diseased kidneys in mice with experimental lupus nephritis. 112 As renal disease is a major contributor to cardiovascular disease, oxidative stress can be expected to also underlie CVD, 20 which is a major cause of morbidity and mortality in SLE along with renal failure and infections. 21 Indeed, IgG antibodies to oxidized phospholipids both elicit atherosclerosis and predispose to nephritis in ApoE -/-Fas -/-mice. 113 
Cardiovascular disease
The accumulation of oxHDL in the blood is associated with accelerated artherosclerosis in patients with SLE, 100 who have 5-8-fold increased age-adjusted incidence of CVD. 114 Malondialdehyde-modified oxidized lowdensity lipoproteins (oxLDL) are implicated in CVD in general, 115 and especially in SLE-associated CVD. 114 HDL, but not oxHDL, protects against the atherogenic effects of oxLDL. 100 Hypertension 116,117 and coronary artery disease have also been associated with oxidative stress in patients with SLE. 117 As noted in the therapeutic section, NAC was found to improve cardiovascular outcomes in patients with end-stage renal disease. 22 Oxidative stress in myeloid cells promotes NETosis and contributes to endothelial cell damage in patients with SLE. 50 
Cutaneous disease
In relation to skin damage, exposure of keratinocytes to UV light triggers exposure of autoantigenic Ro in apoptotic blebs. 98 Thus, via induction of oxidative stress, UV mediates development of photosensitive rash, a common organ manifestation in SLE.
Clinical approaches and implications
Potential biomarker of disease activity No biomarkers of oxidative stress are yet in routine clinical use, but among several candidates it can be hoped that such a test will emerge in the near future. Increased modification of serum albumin by HNE correlates with disease activity in patients with SLE. 102 Urinary levels of F2 isoprostane, a derivative of lipid peroxidation, are associated with disease activity. 118 Oxidized β2GPI is highly specific for the detection of APS in the setting of thrombosis. 119 As mentioned in the section on comorbidities, oxHDL is associated with atherosclerosis in SLE, 100 and oxLDL is a biomarker of CVD. 115 ROI production is detectable in the nephritic kidneys of lupus-prone mice 33 and in the circulation of patients with lupus nephritis. 108 Serum ONOO •-levels positively correlated with disease activity in patients with nephritis. 120 Oxidized phospholipids, such as 1-palmitoyl-2-arachidonoyl-sn-3-glycero-phosphorylcholine, and a series of products derived from them, accumulate in atherosclerotic lesions and are serum markers of oxidative stress in inflammatory diseases, including SLE. 121 Activation of mTOR (Figures 2 and 3) , which is a sensor of mito chondrial hyperpolarization and oxidative stress, has been found to correlate with disease activity and, most importantly, to precede flares in patients with SLE. 34 Target for treatment Therapeutic targeting of oxidative stress includes preventative measures-against exogenous triggers such as UV light and endogenous sources such as mitochondria -as well as stimulation of antioxidant mechanisms. Some interventions are more straightforward than others; photo-resistant clothing and application of sunscreen with protection factor >50, for example, can be used to block UV light. Potential antioxidant therapies include NAC, rapamycin and dietary nutrients such as vitamins (as discussed later in this section), as well as conjugated linoleic acid (CLA). In MRL/lpr mice, CLA increased glutathione synthesis and thus reversed oxidative stress and lupus disease activity, by enhancing the expression of glutamate-cysteine ligase. 122 As we have mentioned, effective antioxidant treat ment might have a role not only in the therapeutic reversal of redox-mediated signalling defects, but also in mitigating the toxicity of immunosuppressive therapies. Indeed, conventional treatment modalities are directed to suppress immune responses, and do so partly by promoting the death of activated and rapidly proliferating self-reactive B cells and T cells. Unwanted consequences can ensue; alkylating agents such as cyclophosphamide, anti-metabolite s (such as mycophenolic acid, 6-mercaptopurin, azathioprine and methotrexate) and corticosteroids (such as prednisone) also elicit toxicity and cell death in the bone marrow and liver through o xidative stress.
1

NAC and rapamycin
As discussed in the section "Altered signal transduction: mTOR and TCR", mTOR is activated by relative depletion of glutathione, the supply of which can be boosted by supplementation with its precursor, NAC, and is diminished by oxidative stress. Acting as a sensor of ∆Ψm, mTOR governs T-cell signalling events implicated in the pathogenesis of SLE. As well as by ensuring an adequate supply of glutathione, mTOR activation can also be prevented by the bacterial-derived antifungal compound rapamycin.
In (NZB × NZW) F1 lupus-prone mice, NAC treatment prevented the decline of glutathione:GSSG ratios, reduced autoantibody production and development of nephritis, and prolonged survival. 110 On the basis of this finding, and that of depleted glutathione in PBL from patients with SLE, 6 we initiated a 3-month phase Iphase II double-blind placebo-controlled randomized pilot study of NAC in 36 patients with SLE, followed by a 1-month washout period, to investigate its safety, tolerability, and metabolic, immunological and therapeutic impact.
7 Although a dose of 1.2 g per day was ineffective, NAC was found to be safe, and doses of 2.4 g per day and 4.8 g per day were effective in reversing glutathione depletion and improving disease activity and fatigue. Blocking activation of mTOR and promoting expansion of CD4 + CD25 + FOXP3 + T-cell subsets, possibly through preventing T-cell activation-induced methylation and silencing of the FOXP3 promoter, 75 NAC treatment was able to inhibit anti-DNA antibody production.
7 Indeed, NAC reversed the expansion of CD4 -
CD8
-T cells, which exhibited the most prominent mTOR activation before treatment with NAC 7 and had been deemed responsible for promoting anti-DNA autoantibody production by B cells. 67 Whereas this proof-of-concept study has clearly shown that NAC can improve disease activity over 3 months in patients with SLE, 7 confirmation in larger cohorts and with longer treatment duration is warranted. Nevertheless, on the basis of its preliminary safety profile and given that it selectively blocks mTOR in T cells, NAC might prove to provide an inexpensive alternative therapy in SLE, and potentially constitutes a synergistic approach to that of B-cell blockade. 1 Good tolerability of NAC might be partly attributable to the improvements in fatigue that it elicited.
7 Benefit in SLE might also result from NAC's reported ability to upregulate HDL-cholesterol, 123 and to reduce the incidence of cardiovascular events, as shown in patients with renal failure. 22 Specific formulations of NAC are approved for use in acetaminophen overdose, contrast nephropathy and cystic fibrosis.
Similar to NAC, rapamycin (used clinically in preventing transplant rejection) also elicits mTOR blockade, although it does so downstream of oxidative stress (Figure 2) . 10 A study of 2 mg per day rapamycin in nine patients with SLE refractory to conventional therapy reported robust clinical improvement, 92 confirmation of which is now being sought in an ongoing prospective phase II clinical trial, in which dosages are titrated to a plasma concentration of 6-15 ng/ml. 34 Interim analysis of data from 24 patients with SLE treated with NAC, and 14 treated with rapamycin, 34 found that in those treated with rapamycin (in whom baseline disease activity was greater), the treatment diminished disease activity and induced the expansion of T REG cells, which might contribute to the therapeutic mechanism. 35 The mechanisms of action of NAC and rapamycin are currently being investigated in animal models, and prospective in-human combination studies of NAC and rapamycin are being planned.
Antioxidant nutrients
Several epidemiological studies have assessed the role of antioxidant nutrient intake in SLE. In a large prospective health survey in 184,643 US women, dietary intake of antioxidant nutrients-vitamins A, C, and E and α-carotene, β-carotene, cryptoxanthin, lycopene, lutein, or zeaxanthin-from foods and supplements was not associated with a decreased risk of developing RA or SLE. 124 These findings suggest that antioxidants are generally safe but do not offer protection against SLE, possibly due to their inability to regulate intra cellular signalling within the immune system. This theory is supported by the results of a double-blind, placebocontrolled 3-month pilot study of 500 mg vitamin C and 800 IU vitamin E daily in 39 patients with SLE, a regimen that reduced plasma levels of malondialdehyde without affecting endothelial function or disease activity. 125 The lack of therapeutic efficacy might relate to insufficient dosing and/or to the inability of vitamin C to augment intracellular glutathione concentrations in T cells, a problem that makes this approach unlikely to succeed. 126 Benefits of compartmentalized oxidative stress Compartmentalized oxidative stress and apoptotic death induced by cytotoxic drugs in highly proliferative auto reactive B cells and T cells is clearly beneficial for REVIEWS patients with SLE; 10-year survival has improved from 50% to 90% since the introduction of cytotoxic and antimetabolite drugs. [127] [128] [129] [130] Nevertheless, this approach can come at a price; the primary cause of death in patients with SLE is infection, 21 secondary to bone-marrow t oxicity and immunosuppression.
Small-molecule therapies in SLE (whether alkylating, such as cyclophosphamide and busulphan, or anti-metabolite, such as azathiprone, mycophenolate and methotrexate; Supplementary Table 1) are all antiproliferative , as are steroid hormones such as prednisone, whereas the mechanism of the anti-malarial agent hydroxychloroquine in SLE seems to involve lysosomal acidification and regulation of autophagy. Alleviating the toxic effects of such drugs is a potential use for anti oxidant therapy such as NAC in SLE, whether or not such therapy proves efficacious against the disease activity in its own right. In a trial of 600 mg NAC versus placebo in 182 patients with interstitial lung disease, for example, concomitant NAC therapy significantly reduced the myelotoxic effects of prednisone and azathio prine. 23 Among questions that remain to be answered in this regard is the extent of NAC's protection against the bone-marrow t oxicity of azathioprine and prednisone when used in SLE. 1 Protection against the development of SLE might be conferred by compartmentalized oxidative stress, but any potential benefits of inducing such stress are likely to be outweighed by associated comorbidities. A protective effect of NOX2 against SLE, as documented in patients with CGD 51 and in MRL/lpr mice, might be mediated through inhibition of NETosis, which involves ox idationdependent destruction of pathogenic bacteria. 52 Reduced capacity to generate oxidative stress in NOX2-deficient neutrophils causes the persistence of bacteria and predisposition to lupus, 13, 51 possibly through stimulation of the innate immune system by bacterial DNA. 131 However, any protective effect of inducing such NOXmediated oxidative stress is likely to be limited. Overall, NOX activity seems rather to have a pathogenic role in promoting CVD, as indicated by its increased expression along with increased production of ROI in and around atherosclerotic plaques in patients with SLE. 132 Likewise, NOX contributes to atherosclerosis in mice; strains lacking p47phox, 133 an essential subunit of NOX2, have diminished disease. 133 These findings indicate the complexity of oxidative stress with respect to comorbidities in SLE.
Conclusions
Overwhelming evidence of increased oxidative stress in SLE that correlates with disease activity and mediates organ damage has been found both in patients with SLE 6,8-10, 101 and in lupus-prone mice. 111, 123 Oxidative stress is a trigger of inflammation, 4 atherosclerosis, 100 CVD, 115 nephritis 33, 108 and APS. 96 Oxidative stress leads to activation of mTOR, which skews lineage specification in T cells.
7,10,34 Reduced capacity to generate oxidative stress can cause the persistence of bacteria and stimulation of the innate immune system by bacterial DNA. 131 Deciphering the roles of compartmentalized oxidative stress in T cells and phagocytic cells in SLE can be expected to provide further insights into the disease pathogenesis. Dietary intake of antioxidant vitamins does not influence the risk of SLE in the general population 124 or improve outcomes; 125 nevertheless, reversal of glutathione depletion reduces disease activity both in lupus-prone mice 110, 122 and patients with SLE. 7 Better characterization of the molecular and cellular sources of oxidative stress that are relevant to SLE will facilitate the development of strategies to minimize and/or reverse the effects of exposure to them and might lead to useful biomarkers of disease activity and response to therapy. We also need to determine the mechanism of mTOR blockade by NAC. Meanwhile, future controlled clinical studies should: evaluate the combination of NAC with rapamycin in terms of potential synergy in efficacy and safety of T-cell inactivation; assess the safety and efficacy of combining NAC with B-cell inhibitors, such as belimumab; and test the protective effect of NAC on bone-marrow and liver toxicity of anti-proliferative drugs, such as cyclophosphamide, azathioprine and mycophenolate. Leveraging beneficial processes of oxidative stress, and suppressing damaging pathways, might thereby ameliorate the effects of chronic therapy, reduce disease activity and improve quality of life for patients with SLE.
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